Profound anemia in a newborn infant of a mother receiving antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 17, Issue 5, 1998, Pages 435-436

  Watson, Wendy J ^a   Stevens, Timothy P ^b   Weinberg, Geoffrey A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ST JOSEPH S HOSPITAL HEALTH CENTER   (United States)

Author keywords

Anemia; Antiretroviral therapy; Neonate

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; LAMIVUDINE; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CONGESTIVE HEART FAILURE; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; MATERNAL DISEASE; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; RETICULOCYTE COUNT; VIRUS LOAD;

ADULT; ANEMIA; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; LAMIVUDINE; LEUKOCYTE COUNT; MALE; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD; ZALCITABINE; ZIDOVUDINE;

EID: 0031802232     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199805000-00022     Document Type: Article

References (10)

1. Centers for Disease Control. AIDS among children: United States, 1996. MMWR 1996;45:1005-10.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
3. Centers for Disease Control. USPHS Task Force recommendations for use of antiretroviral drugs during pregnancy for maternal health and reduction of perinatal transmission of HIV Type 1 in the United States. MMWR 1998;47:1-30.
4. Tugal O, Pallant B, Shebarek N, Jayabose S. Transient erythroblastopenia of the newborn caused by human parvovirus. Am J Pediatr Hematol Oncol 1994;16:352-5.
5. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome: the AIDS Clinical Trials Group. N Engl J Med 1990;323:1009-14.
6. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-106.
7. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine, or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
8. Tseng A, Fletcher D, Gold W, Conly J, Keystone D, Welmsley S. Precipitous declines in hemoglobin with combination ZDV/ 3TC [Abstract 559]. Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Infectious Diseases Society of America, 1997:168.
9. Shah M, Li Y, Christensen RD. Effects of perinatal zidovudine on hematopoiesis: a comparison of effects on progenitors from human fetuses versus mothers. AIDS 1996;10:1239-47.
10. Antiretroviral Pregnancy Registry for didanosine, indinavir, lamivudine, saquinavir, stavudine, zalcitabine. Interim report, January 1, 1989, through December 31, 1996. Research Triangle Park, NC: Glaxo Wellcome, Bristol-Myers Squibb Co., Hoffman-LaRoche Inc., Merck and Co., Inc. Collaborative Project, 1997 (contact information: 1-800-722-9292, ext. 38465).